MX2023002929A - Método para tratamiento del cáncer con protección renal. - Google Patents
Método para tratamiento del cáncer con protección renal.Info
- Publication number
- MX2023002929A MX2023002929A MX2023002929A MX2023002929A MX2023002929A MX 2023002929 A MX2023002929 A MX 2023002929A MX 2023002929 A MX2023002929 A MX 2023002929A MX 2023002929 A MX2023002929 A MX 2023002929A MX 2023002929 A MX2023002929 A MX 2023002929A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- kidney protection
- protoporphyrin
- kidney
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 210000003734 kidney Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 abstract 2
- 229950003776 protoporphyrin Drugs 0.000 abstract 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 abstract 1
- 229940032961 iron sucrose Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062706829P | 2020-09-11 | 2020-09-11 | |
| US202163158803P | 2021-03-09 | 2021-03-09 | |
| PCT/US2021/050064 WO2022056378A1 (en) | 2020-09-11 | 2021-09-13 | Method for treating cancer with kidney protection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002929A true MX2023002929A (es) | 2023-05-22 |
Family
ID=80626052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002929A MX2023002929A (es) | 2020-09-11 | 2021-09-13 | Método para tratamiento del cáncer con protección renal. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220079984A1 (https=) |
| EP (1) | EP4210691A4 (https=) |
| JP (1) | JP2023541606A (https=) |
| KR (1) | KR20230112608A (https=) |
| CN (1) | CN116348107A (https=) |
| AU (1) | AU2021342291A1 (https=) |
| CA (1) | CA3192411A1 (https=) |
| IL (1) | IL301305A (https=) |
| MX (1) | MX2023002929A (https=) |
| WO (1) | WO2022056378A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118103047A (zh) | 2021-08-27 | 2024-05-28 | 美国瑞根特有限公司 | 铁组合物及其制备和使用方法 |
| JPWO2024253189A1 (https=) * | 2023-06-09 | 2024-12-12 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU651758B2 (en) * | 1992-02-07 | 1994-07-28 | Tsumura & Co. | Side-effect alleviant |
| AU6010696A (en) * | 1995-06-10 | 1997-01-09 | Vitra Pharmaceuticals Ltd | Iron compounds, compositions, methods of making the same and uses thereof |
| WO2005094202A2 (en) * | 2004-03-16 | 2005-10-13 | Navinta, Llc | Iron sucrose complexes and method of manufacture thereof |
| DK2262520T3 (en) * | 2008-02-26 | 2017-08-07 | Univ Cornell | COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury |
| SI3200582T1 (sl) * | 2014-09-29 | 2024-04-30 | Fred Hutchinson Cancer Center | Sestave, kompleti in metode za indukcijo pridobljene citorezistence z uporabo induktorjev stresnih proteinov |
| AU2016366668A1 (en) * | 2015-12-11 | 2018-05-31 | Fred Hutchinson Cancer Research Center | Peptides for renal therapy |
| CN119488480A (zh) * | 2019-02-28 | 2025-02-21 | 雷尼布斯治疗公司 | 新型铁组合物及其制造和使用方法 |
-
2021
- 2021-09-13 WO PCT/US2021/050064 patent/WO2022056378A1/en not_active Ceased
- 2021-09-13 US US17/472,954 patent/US20220079984A1/en not_active Abandoned
- 2021-09-13 JP JP2023516137A patent/JP2023541606A/ja active Pending
- 2021-09-13 AU AU2021342291A patent/AU2021342291A1/en not_active Abandoned
- 2021-09-13 CA CA3192411A patent/CA3192411A1/en active Pending
- 2021-09-13 CN CN202180070528.4A patent/CN116348107A/zh active Pending
- 2021-09-13 IL IL301305A patent/IL301305A/en unknown
- 2021-09-13 MX MX2023002929A patent/MX2023002929A/es unknown
- 2021-09-13 EP EP21867758.1A patent/EP4210691A4/en not_active Withdrawn
- 2021-09-13 KR KR1020237011800A patent/KR20230112608A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL301305A (en) | 2023-05-01 |
| EP4210691A4 (en) | 2025-02-26 |
| BR112023004583A2 (pt) | 2023-04-11 |
| WO2022056378A1 (en) | 2022-03-17 |
| AU2021342291A1 (en) | 2023-04-20 |
| JP2023541606A (ja) | 2023-10-03 |
| EP4210691A1 (en) | 2023-07-19 |
| CN116348107A (zh) | 2023-06-27 |
| US20220079984A1 (en) | 2022-03-17 |
| KR20230112608A (ko) | 2023-07-27 |
| CA3192411A1 (en) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| ZA201906001B (en) | Combination therapy for the treatment or prevention of tumours | |
| MX2017016491A (es) | Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor). | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| PH12012502380B1 (en) | Methods of treatment of pancreatic cancer | |
| PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| MX2022015748A (es) | Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer. | |
| WO2019126739A8 (en) | Pyrvinium pamoate anti-cancer therapies | |
| MX2023002929A (es) | Método para tratamiento del cáncer con protección renal. | |
| MX394425B (es) | Terapia de combinación con bromodominio e inhibidor de proteína extra terminal. | |
| MX2019014059A (es) | Adenovirus antiangiogenico. | |
| TW201613589A (en) | Combination methods for treating cancers | |
| WO2018064588A3 (en) | Tert immunogenic compositions and methods of treatment using the same | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| PH12020552171A1 (en) | Bifunctional compositions for the treatment of cancer | |
| ZA202301066B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| CO2019009000A2 (es) | Combinaciones farmacéuticas para tratar cáncer | |
| WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| NZ801252A (en) | Pharmaceutical composition comprising insoluble camptothecin compound-containing nanoparticle for treatment of cancer and combination therapy thereof | |
| MY205171A (en) | Methods of treatment of hypertriglyceridemia | |
| WO2017117386A8 (en) | Methods of treating cancer using network brakes |